Lone

Lone is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients suffering from advanced heart failure. The company's lead product, Algisyl-LVR, is an implantable biopolymer hydrogel that acts as a left ventricular restoration (LVR) device to improve cardiac function by reducing wall stress. Beyond its mechanical interventions, Lone is advancing a pipeline of small molecules, such as isoxazoles, and cellular therapies aimed at reprogramming cardiac fibroblasts and modulating stem cells. By combining surgical devices with regenerative medicine, the company seeks to provide comprehensive solutions for restoring the failing heart's structure and efficiency.